Scopus BioPharma announces the adjournment of the annual meeting of


NEW YORK, October 08, 2021 (GLOBE NEWSWIRE) – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapies for serious illnesses with significant unmet medical need, today announced that on October 8, 2021, its 2021 annual meeting of shareholders (the “annual meeting”) was adjourned to 1:00 p.m. Eastern Time on Friday, November 5, 2021, with no case proceeding, pursuant to a stipulation and court order approved by the Delaware Court of Chancellery between Scopus and Morris C Laster, MD in connection with Dr. Laster’s pending claims against Scopus in the Delaware Court of Chancery. Notwithstanding the stipulation and court order requiring Dr. Laster to cause all of the common shares of Scopus that he holds to be present in person or by proxy at the annual meeting and any adjournment thereof exclusively for the purposes of to establish a quorum at the meeting, Dr. Laster failed to meet this requirement by not attending the annual meeting in person and by not having his shares presented by proxy.

The adjourned meeting will be held via remote communication and can be accessed through the following URL: The closing date for the Annual Meeting will remain August 16, 2021.

Scopus continues to solicit votes from its shareholders with respect to the proposals set out in Scopus’ proxy circular dated September 16, 2021. Proxies previously submitted in respect of the Annual Meeting will be voted on at the Annual Meeting adjourned, unless they are duly revoked, and shareholders who have already submitted a proxy or voted otherwise and who do not want to change their vote do not need to take action.

Scopus encourages all shareholders who are holding their shares at the close of business on August 16, 2021 and have not yet voted to do so as soon as possible. Shareholders who have questions or need help filling out a form of proxy or voting instructions, or who do not have the required documents, can contact Scopus’ attorney, Morrow Sodali LLC, by calling toll-free transferred to (203) 561-6945 or toll free at (800) 662-5200 or by sending an e-mail to [email protected]

About Scopus BioPharma

Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapies for serious illnesses with significant unmet medical needs. The Company’s lead drug candidate is a novel targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate is very distinctive, encompassing both RNA therapy and immunotherapy by synthetically binding siRNA to a TLR9 oligonucleotide agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and activation. immune system in the tumor microenvironment. Other immunotherapy drug candidates targeting STAT3 include bifunctional antisense and DNA binding inhibition therapies. The company is also looking to develop other drug candidates and identify other interesting technologies for potential acquisitions, licenses and / or other similar transactions. Receive updates by following Scopus BioPharma on Twitter here.

Forward-looking statements

This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. These forward-looking statements are subject to risks (including those set forth in the Company’s Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the Securities and Exchange Commission (“SEC”)) and uncertainties. which could cause actual results to differ from forward-looking statements. The company expressly disclaims any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in the company’s expectations in this regard or any change in events, conditions or circumstances on which a statement is based on. Investors should be aware that if our assumptions underlying the projections contained herein prove to be incorrect or known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations and projections. In addition, there can be no assurance that the company will identify and / or complete a transaction relating to additional technologies.


Rodd Leeds / David Waldman
Crescendo Communications, LLC
Phone. : (212) 671-1020
Email: [email protected]

Hugh Burns / Delia Cannan / Nicholas Leasure
Phone. : (212) 433-4600
Email: [email protected]

Source link

Leave A Reply

Your email address will not be published.